Table 4 Efficacy of IL-2 in treating MPE
Study | Study size (N) | Study design | Efficacy of therapy | Improvement of QOL (N; %) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |||||||||||
Group 1 | Group 2 | CR | PR | SD | PD | CR | PR | SD | PD | N | % | N | % | |||
Changjie H 2001 [15] | 30 | 30 | Cisplatin+IL-2 | Cisplatin | 16 | 10 | 4 | 6 | 8 | 16 | – | – | – | – | ||
Xiuzhi Y 2001 [16] | 40 | 20 | Cisplatin+IL-2 | Cisplatin | 17 | 19 | 5 | 8 | 7 | 5 | – | – | – | – | ||
Zhuo S 2004 [17] | 32 | 30 | Cisplatin+IL-2 | Cisplatin | 14 | 12 | 4 | 2 | 5 | 10 | 6 | 9 | 20 | 63 | 11 | 37 |
Junyan W 2005 [18] | 48 | 34 | Cisplatin+IL-2 | Cisplatin | 25 | 14 | 9 | 12 | 8 | 14 | – | – | – | – | ||
Haiying X 2009 [19] | 35 | 28 | Cisplatin+IL-2 | Cisplatin | 10 | 18 | 7 | 3 | 12 | 13 | – | – | – | – | ||
Xiaoxia H 2009 [20] | 37 | 35 | Cisplatin+IL-2 | Cisplatin | 15 | 16 | 3 | 3 | 8 | 11 | 7 | 9 | 29 | 78.3 | 19 | 54.3 |
Lizheng C 2009 [21] | 46 | 40 | Cisplatin+IL-2 | Cisplatin | 26 | 13 | 7 | 13 | 10 | 17 | – | – | – | – | ||
Jinguang C 2009 [22] | 31 | 31 | Cisplatin+IL-2 | Cisplatin | 12 | 17 | 2 | 7 | 13 | 11 | – | – | – | |||
Junfeng W 2010 [23] | 41 | 41 | Cisplatin+IL-2 | Cisplatin | 29 | 4 | 3 | 5 | 7 | 15 | 3 | 16 | – | – | – | – |
Jingping Z 2010 [24] | 63 | 61 | Cisplatin+IL-2 | Cisplatin | 25 | 30 | 5 | 3 | 12 | 22 | 4 | 23 | – | – | – | – |
Cheng X 2010 [25] | 41 | 41 | Cisplatin+IL-2 | Cisplatin | 21 | 17 | 3 | 13 | 8 | 20 | – | – | – | – | ||
Fang S 2011 [26] | 30 | 30 | Cisplatin+IL-2 | Cisplatin | 9 | 17 | 4 | 7 | 14 | 9 | 26 | 86.7 | 24 | 80 | ||
Xueling L 2011 [27] | 34 | 34 | Cisplatin+IL-2 | Cisplatin | 19 | 11 | 4 | 8 | 10 | 16 | – | – | – | – | ||
Yan Q 2011 [28] | 41 | 35 | Cisplatin+IL-2 | Cisplatin | 12 | 24 | 3 | 2 | 6 | 12 | 4 | 13 | – | – | – | – |
Li J 2013 [29] | 38 | 35 | Cisplatin+IL-2 | Cisplatin | 12 | 13 | 13 | 4 | 11 | 20 | 27 | 71.1 | 17 | 48.6 | ||
Lijie H 2014 [30] | 30 | 30 | Cisplatin+IL-2 | Cisplatin | 12 | 13 | 5 | 7 | 10 | 13 | 26 | 86.7 | 19 | 63.3 | ||
Miao H 2016 [31] | 31 | 30 | Cisplatin+IL-2 | Cisplatin | 11 | 15 | 5 | 7 | 10 | 13 | – | – | – | – | ||
Baohua Y 2017 [32] | 33 | 33 | Cisplatin+IL-2 | Cisplatin | 11 | 18 | 3 | 1 | 8 | 14 | 6 | 5 | – | – | – | – |